Aveo Pharmaceuticals Stock News

Analysts forecast that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will announce $23.39 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for AVEO Pharmaceuticals earnings, with the lowest sales estimate coming in at $22.80 million and the highest estimate coming in at $23.76 million. AVEO Pharmaceuticals posted sales of $890,000.00 in []

Related Stocks: SCPH , OIIM , PRTK , PGR , FC , APPS , SIMO , ADTN , AVEO , HGV , FKWL , AMSC , ASPN , AVYA , HOME , RCL , ARDS , SNPX ,

Los Angeles, USA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Promising Treatment for Advanced Hepatocellular Carcinoma Enters Clinical Trials | DelveInsight There are a plethora of companies developing therapies to treat Advanced Hepatocellular Carcinoma. CStone Pharmaceuticals has its drug candidate in the most advanced stage (Phase III). DelveInsight''s " Advanced Hepatocellular Carcinoma Pipeline Insight " report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Advanced Hepatocellular Carcinoma pipeline landscapes. It comprises Advanced Hepatocellular Carcinoma pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Advanced Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Advanced Hepatocellular Carcinoma pipeline products. Some of the key takeaways from the Advanced Hepatocellular Carcinoma Pipeline Report Major companies such as CStone Pharmaceuticals, Akesobio, Chia Tai Tianqing Pharmaceutical Group, Yiviva Inc., BeiGene, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Carsgen Therapeutics, Ltd., Jiangsu Alphamab Biopharmaceuticals, Sunshine Lake Pharma Co., Ltd., AVEO Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd., Sinocelltech Ltd., LTD, Eureka Therapeutics Inc., Taizhou Hanzhong biomedical co.

AVEO Pharmaceuticals, Inc. (AVEO) CEO Michael Bailey on Q3 2021 Results - Earning Call Transcript

AVEO (AVEO) delivered earnings and revenue surprises of 16.67% and 6.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

KRBN invests in carbon credits, which have seen skyrocketing prices. The fund has significantly outperformed its peers since inception and seems set to continue to do so.

AVEO Pharmaceuticals, Inc. (AVEO) CEO Michael Bailey on Q2 2021 Results - Earnings Call Transcript

Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 4.76% year over year to ($0.40),

AVEO Pharmaceuticals: Making Its Mark In Cancer Treatment

AVEO Oncology: Time To Be Patient

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced the presentation of additional data from the Phase 3 TIVO-

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced results from a randomized confirmatory Phase 2 study of fi

AVEO Pharmaceuticals, Inc. (AVEO) CEO Michael Bailey on Q1 2021 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report first quarter 2021 financial results o